Stanley TL et al., "Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial," The Lancet HIV, 2019
Currently available GLP-1 receptor agonists in the United States include exenatide (Byetta, Bydureon BCise), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), semaglutide (Ozempic, Wegovy, Rybelsus), and tirzepatide (Mounjaro, Zepbound), though tirzepatide is technically a dual GIP/GLP-1 receptor agonist
This localized, multi-pathway approach provides a dependable option for sustained joint relief without reliance on systemic dosing
About this article Cite this article Wirth, T., Faber, J., Depienne, C
Important: GHK-Cu is a research compound and is not FDA-approved
(1979) Ethylene oxide: evidence of human chromosomal effects